About Versantis
Versantis is a company based in Zurich (Switzerland) founded in 2015 by Meriam Kabbaj and Vincent Forster was acquired by Genfit in September 2022. Versantis has raised $20.51 million across 3 funding rounds from investors including HealthEquity, Zurcher Kantonalbank and Genfit. Versantis operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter Zurich, Switzerland
- Founders Meriam Kabbaj, Vincent Forster
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website versantis.com
- Social LinkedIn X
- Acquired by Genfit (Sep 2022)
- Total Equity Funding$20.51M (USD)
in 3 rounds
- Latest Funding Round$509.71K (USD), Grant
Apr 2022
- InvestorsHealthEquity
& 9 more
- Acquired byGenfit
(Sep 2022)
Funding Insights of Versantis
Versantis has successfully raised a total of $20.51M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $509.71 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.51M
- Total Rounds 3
- Last Round Grant — $509,713
- First Round $4.4M
(Mar 2017)
- Investors Count 9
All 3 funding rounds of Versantis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $509,713 | Grant | – | – | |
| Sep 2019 | $16.11M | Series B | – | Swisscanto | |
| Mar 2017 | $4.4M | Series A | – | Venture Kick, Redalpine | – |
10 investors in total: 10 institutional.
Investors in Versantis
Versantis has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include HealthEquity, Zurcher Kantonalbank and Genfit.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are directed toward ICT and health tech startups. | – | redalpine.com | Zurich, Switzerland | |
Esperante is focused on innovative life science investments. | – | esperante.com | Hoofddorp, Netherlands | |
University backed startup accelerator | – | venturekick.ch | Schlieren, Switzerland | |
Venture capital investments are provided to deep-tech startups. | – | occident.group | Munich, Germany | |
Innosuisse is engaged in promoting innovation across Swiss organizations. | – | innosuisse.ch | Switzerland | |
Diversified investment management services are provided by Swisscanto in Switzerland. | 1973 | swisscanto.com | Switzerland | |
Health benefits and savings are managed through an app-based platform. | 2002 | healthequity.com | Draper, United States | |
Long/short strategies are employed in hedge fund management. | 2009 | altus-partners.com | London, United Kingdom | |
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank. | 1870 | zkb.ch | Zurich, Switzerland | |
Therapeutics for cardiometabolic and neurodegenerative diseases. | 1999 | genfit.com | Loos, France |
Investor details for Versantis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Versantis
2 people are tracked at Versantis (2 in leadership).
| Name | Role | Group |
|---|---|---|
Meriam Kabbaj | Co-Founder & COO | Leadership |
Vincent Forster | Co-Founder & CSO | Leadership |
Complete people profiles for Versantis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Versantis
4 dated milestones of Versantis across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Versantis is founded.
- Funding First funding round of $4.4M.
- Funding Latest funding round, Grant, of $510K.
- Exit Acquired by Genfit.
Competitors of Versantis
Versantis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Mirum Pharmaceuticals, Madrigal Pharmaceuticals and Akero Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. | |
| madrigalpharma.com | 2011 | Conshohocken, United States | $38.38M | 56 | Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis | |
| akerotx.com | 2017 | San Francisco, United States | $135M | 33 | Small molecule therapeutics for metabolic disorders are developed. | |
| enyopharma.com | 2014 | Lyon, France | $120.34M | – | Therapeutics are developed for diseases with impaired kidney function. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| ternspharma.com | 2017 | San Mateo, United States | $207.7M | 46 | Therapies for liver disease and cancer are developed. | |
| cymabay.com | 1991 | Hayward, United States | $276.71M | 23 | Developer of therapeutics for liver and other chronic diseases | |
| healx.ai | 2014 | Cambridge, United Kingdom | $115.37M | 80 | AI-powered drug discovery platform for rare diseases is developed. |
Detailed competitors of Versantis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Versantis
Complete news archive for Versantis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Versantis
10 companies that operate in the same segment as Versantis (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 533 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Versantis
Versantis was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Versantis is headquartered in Zurich, Switzerland.
Versantis is a funded company, having raised a total of $20.51M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.4M, raised on Mar 2017.
Versantis was founded in 2015 in Zurich, Switzerland, as a biotechnology firm focused on orphan and rare pediatric liver disorders. Drugs are developed to address late-stage liver diseases, such as hepatic encephalopathy and hepatorenal syndrome. The lead candidate, VS-01, targets acute-on-chronic liver failure. Operations center on advancing therapies for patients with limited treatment options in this specialized sector.
Versantis's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
Versantis has 10 investors. Key investors include HealthEquity, Zurcher Kantonalbank, Genfit, Swisscanto, and Altus Partners.
Yes. Versantis was acquired by Genfit in September 2022.